Table S3. Univariate Cox regression analysis of overall survival with ICI in patients with advanced LCNEC (group A* (n = 36); statistically significant differences are bold). *Anti-PD-1/PD-L1 agent administered as a monotherapy (mono) vs combination of anti-PD-1 and anti-CTLA4 agents (doublet). Abbreviations: 

CTLA4 - cytotoxic T-lymphocyte-associated protein 4; DX - diagnosis; ECOG PS - Eastern Cooperative Oncology Group performance status score; ICI - immune check-point inhibitors; LCNEC - large cell neuroendocrine tumors of lung; mono - monotherapy; NSCLC - non-small-cell lung cancer; PD-1 - programmed cell death-1; PD-L1 - programmed cell death ligand-1; Tx – treatment.